Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Double-blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy and Safety of AR882 in Participants with Gout

Next Previous
X
Search
Trial Profile

A Phase 3 Randomized, Double-blind, Multi-center, Placebo-controlled Study to Evaluate the Efficacy and Safety of AR882 in Participants with Gout

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Mar 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AR 882 (Primary)
  • Indications Gout
  • Focus Registrational; Therapeutic Use
  • Acronyms REDUCE 2
  • Sponsors Arthrosi Therapeutics

    • Most Recent Events

    • 05 Mar 2025 According to an Arthrosi Therapeutics media release, company announced the completion of enrollment in this study. and company expects to complete this trial in the first half of 2026.
    • 05 Mar 2025 Status changed from recruiting to active, no longer recruiting, According to an Arthrosi Therapeutics media release.
    • 18 Dec 2024 According to an Arthrosi Therapeutics media release, company shows intention that its pivotal phase 3 program will support a comprehensive New Drug Application to the U.S. Food and Drug Administration in all gout patients.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top